

# Human tandem-repeat-type galectins bind bacterial non- $\beta$ Gal polysaccharides

Yu. A. Knirel · H.-J. Gabius · O. Blixt · E. M. Rapoport ·  
N. R. Khasbiullina · N. V. Shilova · N. V. Bovin

Received: 24 June 2013 / Revised: 10 August 2013 / Accepted: 19 August 2013 / Published online: 25 September 2013  
© Springer Science+Business Media New York 2013

**Abstract** Galectins are multifunctional effectors, for example acting as regulators of cell growth via protein-glycan interactions. The observation of capacity to kill bacteria for two tandem-repeat-type galectins, which target histo-blood epitopes toward this end (Stowell *et al.* Nat. Med. 16:295–301, 2010), prompted us to establish an array with bacterial polysaccharides. We addressed the question whether sugar determinants other than  $\beta$ -galactosides may be docking sites, using human galectins-4, -8, and -9. Positive controls with histo-blood group ABH-epitopes and the *E. coli* 086 polysaccharide ascertained the suitability of the set-up. Significant signal generation, depending on type of galectin and polysaccharide, was obtained. Presence of cognate  $\beta$ -galactoside-related epitopes within a polysaccharide chain or its branch will not automatically establish binding properties, and structural constellations lacking galactosides, like rhamnan, were found to be active. These data establish the array as valuable screening tool, giving direction to further functional and structural studies.

**Keywords** ABO · Bacterial polysaccharide · Galectin · Glycan · Printed glycan array · Rhamnoside

## Abbreviations

BSA Bovine serum albumin  
CRD Carbohydrate recognition domain  
PS Polysaccharide  
RFU Relative Fluorescence Units

## Introduction

Epitopes of glycan chains of natural glycoconjugates are increasingly delineated as biochemical signals, their information turned into cellular effects by lectins [1, 2]. In addition to endogenous glycan determinants, tissue lectins, *e.g.* C-type lectins and galectins, have the ability to target pathogens, as part of defence mechanisms or exploited as sites for bacterial/viral/yeast attachment [3–6]. From the family of galectins, which share the  $\beta$ -sandwich fold, a sequence signature and specificity to  $\beta$ -galactosides, special attention has so far been given to galectin-3 with respect to bacterial recognition [4, 7]. The binding of this chimera-type protein (with its tridomain structure constituted by an N-terminal section, collagen-like repeats and the carbohydrate recognition domain (CRD)) involves carbohydrate-dependent/independent mechanisms. Interest in studying galectins was recently further stimulated by the observation that the tandem-repeat-type galectins-4 and -8 (proteins with two CRDs covalently connected by a linker [8]) can abolish bacterial viability after targeting histo-blood group B antigen on *E. coli* 086 surface [9]. In fact, the repeating unit of its O-polysaccharide (PS) [10] mimics the B (type 4) antigen. Overall, rather strong interaction with histo-blood group epitopes had been reported for the tandem-repeat-type galectins-4, -8, and -9 by different methods [9, 11–15]. Using a cell-based assay, which measures the ligand selection

Y. A. Knirel  
N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky prosp., 47, Moscow 119991, Russian Federation


H.-J. Gabius  
Institute of Physiological Chemistry, Faculty of Veterinary Medicine, Ludwig Maximilians University, Veterinarstr. 13, 80539 Munich, Germany

O. Blixt  
Department of Chemistry, Faculty of Science, University of Copenhagen, Thorvaldsensvej 40, DK-1871 Copenhagen, Denmark  
e-mail: olablixt@chem.ku.dk


E. M. Rapoport · N. R. Khasbiullina · N. V. Shilova ·  
N. V. Bovin (✉)  
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya 16/10, 117997 Moscow, Russia  
e-mail: bovin@carb.ibch.ru

of cell-bound galectins for cross-linking, a clear preference for such epitopes had even been revealed (Fig. 1) [16, 17].

This preference is phylogenetically conserved, pointing to a physiological role [18] and hereby directing interest to characterizing the range of potential binders among bacterial PSs. The occurrence of such epitopes in PSs of infectious bacteria is very low. Inspection of the relevant public database at <http://csdb.glycoscience.ru>, which covers about 10,000 structures from around 5,000 organisms, demonstrates that only few of them contain ABH-like motifs, including the polysaccharide from *E. coli* O86 mentioned above:



and an oligosaccharide from *Helicobacter mustelae* strain ATCC43772 terminating with the A (type 1) tetrasaccharide:



Since the mode of epitope presentation is known to affect galectin reactivity [19, 20], the first aim of our study is to figure out whether epitope presence will translate into binding activity. Also, molecular mimicry may endow PSs without  $\beta$ -galactosides, the canonical ligands, with binding capacity, warranting a robust screening. Experimentally, we established an array of PSs from bacteria of the genera *Escherichia*, *Shigella*, *Salmonella*, *Cronobacter*, *Proteus*, and *Pseudomonas*, putting together a total of nearly 150 structurally defined polysaccharides (Table 1). The array also contained a set of non-bacterial glycans as controls, including ABH epitopes [21].

## Material and methods

### Reagents

Carbohydrate-free bovine serum albumin (BSA),  $\text{Na}_2\text{HPO}_4$ ,  $\text{NaH}_2\text{PO}_4$ , NaCl and KCl were purchased from Sigma (USA), Tween-20 was from ICN (USA). Alexa-555-labeled streptavidin was obtained from Invitrogen (USA).

### Galectins


Recombinant human galectins -4, -8 and -9 were produced using suited vector/bacteria systems as described and then purified from extracts by affinity chromatography on lactosylated Sepharose 4B [22, 23]. Homogeneity was ascertained by gel filtration, also removing any cleaved material such as free CRDs, and by one/two-dimensional gel electrophoreses, biotinylation performed as described in detail previously [24] and carbohydrate-dependent activity tested by solid-phase/cell assays [25, 26].

### Glycans

Polysaccharides were obtained by mild acid degradation (2 % HOAc, 100 °C, 1–4 h) of the corresponding lipopolysaccharides isolated from bacterial cells by the Westphal procedure [27] modified as described [28]. The polysaccharides were purified by gel-permeation chromatography on Sephadex G-50 (Superfine) in pyridinium acetate buffer (4 mL pyridine and 10 mL HOAc in 1 L water). Oligosaccharides in form of aminopropyl-, aminoethyl- or glycyamido-glycosides are described in [21].

### Glycan array

Microarrays on glass microscope slides presenting the oligosaccharides and polysaccharides were printed as described



**Fig. 1** Elevated affinity of galectins -4, -8 and -9 towards blood group A and B (types 1 and 2) glycans, data taken from [3] and [4] are shown as partial ‘weight’ of the corresponding glycan. LN Gal $\beta$ 1-4GlcNAc, Le<sup>C</sup>

Gal $\beta$ 1-3GlcNAc, T $\beta\beta$  Gal $\beta$ 1-3GalNAc $\beta$ , A<sub>tetra</sub> GalNAc $\alpha$ 1-3(Fuc $\alpha$ 1-2)Gal $\beta$ 1-4GlcNAc, B<sub>tetra</sub> Gal $\alpha$ 1-3(Fuc $\alpha$ 1-2)Gal $\beta$ 1-4GlcNAc

**Table 1** List of bacterial strains used for isolation of the polysaccharides included into the array

№	Name
1	<i>Salmonella enterica</i> O28deAc
2	<i>Salmonella enterica</i> O47deAc
3	<i>Salmonella enterica</i> O16deAc
4	<i>Salmonella enterica</i> O13
5	<i>Salmonella enterica</i> O28
6	<i>Salmonella enterica</i> O16
7	<i>Salmonella enterica</i> O17
8	<i>Salmonella enterica</i> O67
9	<i>Salmonella enterica</i> O58
10	<i>Salmonella enterica</i> O41
11	<i>Salmonella enterica</i> O62
12	<i>Salmonella enterica</i> O60
13	<i>Salmonella enterica</i> O18
14	<i>Salmonella enterica</i> O59
15	<i>Salmonella enterica</i> O42
16	<i>Salmonella enterica</i> O52
17	<i>Salmonella enterica</i> O11
18	<i>Salmonella enterica</i> O51
19	<i>Salmonella enterica</i> O44
20	<i>Salmonella enterica</i> O21
21	<i>Salmonella enterica</i> O57
22	<i>Salmonella enterica</i> O56
23	<i>Salmonella enterica</i> O38
24	<i>Cronobacter sakazaki</i> G2356 O2
25	<i>Cronobacter sakazaki</i> G2592 O7
26	<i>Cronobacter sakazaki</i> G2594 O4
27	<i>Cronobacter sakazaki</i> G2726 O3
28	<i>Escherichia coli</i> O11
29	<i>Escherichia coli</i> O15
30	<i>Escherichia coli</i> O44
31	<i>Escherichia coli</i> O49
32	<i>Escherichia coli</i> O51
33	<i>Escherichia coli</i> O52
34	<i>Escherichia coli</i> O57
35	<i>Escherichia coli</i> O58
36	<i>Escherichia coli</i> O71
37	<i>Escherichia coli</i> O73
38	<i>Escherichia coli</i> O85
39	<i>Escherichia coli</i> O86
40	<i>Escherichia coli</i> O95
41	<i>Escherichia coli</i> O99
42	<i>Escherichia coli</i> O108
43	<i>Escherichia coli</i> O112ab
44	<i>Escherichia coli</i> O118
45	<i>Escherichia coli</i> O119
46	<i>Escherichia coli</i> O123
47	<i>Escherichia coli</i> O125
48	<i>Escherichia coli</i> O127

**Table 1** (continued)


№	Name
49	<i>Escherichia coli</i> O130
50	<i>Escherichia coli</i> O148
51	<i>Escherichia coli</i> O150
52	<i>Escherichia coli</i> O151
53	<i>Escherichia coli</i> O161
54	<i>Escherichia coli</i> O168
55	<i>Escherichia coli</i> O10a,O10b
56	<i>Escherichia coli</i> O12
57	<i>Escherichia coli</i> O14
58	<i>Escherichia coli</i> O19ab
59	<i>Escherichia coli</i> O27
60	<i>Escherichia coli</i> O36
61	<i>Escherichia coli</i> O37
62	<i>Escherichia coli</i> O41
63	<i>Escherichia coli</i> O54
64	<i>Escherichia coli</i> O62
65	<i>Escherichia coli</i> O81
66	<i>Pseudomonas aeruginosa</i> O1(F4)
67	<i>Pseudomonas aeruginosa</i> O10ac(F5)
68	<i>Pseudomonas aeruginosa</i> O11ab
69	<i>Pseudomonas aeruginosa</i> O13ab
70	<i>Pseudomonas aeruginosa</i> O13ac
71	<i>Pseudomonas aeruginosa</i> O14
72	<i>Pseudomonas aeruginosa</i> O15
73	<i>Pseudomonas aeruginosa</i> O2abc
74	<i>Pseudomonas aeruginosa</i> O2ac
75	<i>Pseudomonas aeruginosa</i> O2ac(F3)
76	<i>Pseudomonas aeruginosa</i> O2adf
77	<i>Pseudomonas aeruginosa</i> O3(Habs 3)
78	<i>Pseudomonas aeruginosa</i> O4ac
79	<i>Pseudomonas aeruginosa</i> O9ad
80	<i>Proteus genomospecies</i> 11B-r
81	<i>Proteus mirabilis</i> 12B-r
82	<i>Proteus mirabilis</i> 1B-m
83	<i>Proteus mirabilis</i> 3B-m
84	<i>Proteus mirabilis</i> O11
85	<i>Proteus mirabilis</i> O13
86	<i>Proteus mirabilis</i> O16
87	<i>Proteus mirabilis</i> O23
88	<i>Proteus mirabilis</i> O28
89	<i>Proteus mirabilis</i> O31
90	<i>Proteus mirabilis</i> O33
91	<i>Proteus mirabilis</i> O38
92	<i>Proteus mirabilis</i> O3ac
93	<i>Proteus mirabilis</i> O58
94	<i>Proteus mirabilis</i> O6
95	<i>Proteus mirabilis</i> O60
96	<i>Proteus mirabilis</i> OE
97	<i>Proteus pinneri</i> 107

**Table 1** (continued)

No	Name
98	<i>Proteus pinneri</i> 113
99	<i>Proteus pinneri</i> 28
100	<i>Proteus pinneri</i> 31
101	<i>Proteus pinneri</i> 40
102	<i>Proteus pinneri</i> 75
103	<i>Proteus vulgaris</i> 32/57 O17
104	<i>Proteus vulgaris</i> O19ab
105	<i>Proteus vulgaris</i> O22
106	<i>Proteus vulgaris</i> O4
107	<i>Proteus vulgaris</i> O46
108	<i>Proteus vulgaris</i> O65
109	<i>Proteus vulgaris</i> OX19
110	<i>Proteus vulgaris</i> TG251
111	<i>Shigella boydii</i> type 10
112	<i>Shigella boydii</i> type 12
113	<i>Shigella boydii</i> type 14
114	<i>Shigella boydii</i> type 15
115	<i>Shigella boydii</i> type 16
116	<i>Shigella boydii</i> type 17
117	<i>Shigella boydii</i> type 18
118	<i>Shigella boydii</i> type 2
119	<i>Shigella boydii</i> type 6
120	<i>Shigella boydii</i> type 7
121	<i>Shigella boydii</i> type 8
122	<i>Shigella boydii</i> type 9
123	<i>Shigella boydii</i> type X
124	<i>Shigella dysenteriae</i> type 1
125	<i>Shigella dysenteriae</i> type 11
126	<i>Shigella dysenteriae</i> type 3
127	<i>Shigella dysenteriae</i> type 4
128	<i>Shigella dysenteriae</i> type 7
129	<i>Shigella dysenteriae</i> type 8
130	<i>Shigella dysenteriae</i> type 8
131	<i>Shigella dysenteriae</i> type 9
132	<i>Shigella flexneri</i> type 2a
133	<i>Shigella flexneri</i> type 2b
134	<i>Shigella flexneri</i> type 3a
135	<i>Shigella flexneri</i> type 3b
136	<i>Shigella flexneri</i> type 4a
137	<i>Shigella flexneri</i> type 4b
138	<i>Shigella flexneri</i> type 5a
139	<i>Shigella flexneri</i> type 5b
140	<i>Shigella flexneri</i> type 6
141	<i>Shigella flexneri</i> type 6b
142	<i>Shigella flexneri</i> type X
143	<i>Shigella flexneri</i> type Y
144	<i>Streptococcus equi</i> sp.
145	<i>Acetobacter methanolicus</i> LPS
146	<i>Saccharomyces cerevisiae</i> (Zymosan A)

**Table 1** (continued)

No	Name
147	Laminarin from <i>L. hyperborea</i>
148	Barley $\beta$ -glucan
149	Scleroglucan
150	Curdlan
151	high MW chitosan

**Fig. 2** Binding of galectins to bacterial polysaccharides immobilized on microchip compared to trisaccharide H (type 1) and tetrasaccharide B (type 4). Other PSs listed in Table 1 were also assayed, no binding was observed. Background of the assay is considered as ~500 RFU

**Table 2** Structures of the repeating units of bacterial PSs reactive with tandem-repeat-type galectins (structural information from <http://csdb.glycoscience.ru>). Histo-blood group H- and B-motifs are shown in bold

Bacterium	Structure of the repeating unit
<i>Salmonella enterica</i> O13	$[-2\text{Fuc}\alpha 1-2\text{Gal}\beta 1-3\text{GalNAc}\beta 1-3\text{GlcNAc}\beta 1-]_n$
<i>E. coli</i> O19ab	$[-2\text{Rha}\alpha 1-2\text{Rha}\alpha 1-2\text{Rha}\alpha 1-2\text{Glc}\beta 1-3\text{GlcNAc}6\text{Ac}\beta 1-]_n$
<i>E. coli</i> O86	$[-2\text{Gal}\alpha 1-3(\text{Fuc}\alpha 1-2)\text{Gal}\beta 1-3\text{GalNAc}\alpha 1-3\text{GalNAc}\beta 1-]_n$
<i>Shigella flexneri</i> type X	$[-2(\text{Glc}\beta 1-3)\text{Rha}\alpha 1-2\text{Rha}\alpha 1-3\text{Rha}\alpha 1-3\text{Glc}\beta 1-3\text{GlcNAc}\beta 1-]_n$
<i>Shigella dysenteriae</i> type 7	$[-3\text{Qui}4\text{NGlyAc}\beta 1-4\text{GalNAc}6\text{NH}_2\text{3Ac}\alpha 1-4\text{GalNAc}\alpha 1-3\text{GlcNAc}\alpha 1-]_n$

[29]. Aliquots of solution of biotinylated galectins (75  $\mu\text{g}/\text{ml}$ ) in PBS (0.01 M  $\text{Na}_2\text{HPO}_4$ , 0.01 M  $\text{NaH}_2\text{PO}_4$ , 0.138 M NaCl, and 0.0027 M KCl, pH 7.4) containing 1 % BSA were applied to slides (pretreated with PBS containing 0.1 % Tween-20 for 15 min) and incubated in a humidified chamber at 20 °C for 1 h. Therefore, the slides were washed with PBS containing 0.05 % Tween-20 and incubated with a streptavidin-Alexa-555 conjugate (diluted 1:1,000 with PBS containing 0.1 % Tween-20) under the same conditions. After washing with PBS containing 0.05 % Tween-20 and deionized water, slides were scanned on a ProScanArray HT scanner (PerkinElmer, USA) using the excitation wavelength 543 nm. The obtained data were processed using ScanArray Express 3.0 software and the fixed 70  $\mu\text{m}$ -diameter rings method as well as Microsoft Excel. Twelve spots represent each glycan on the array and data are reported as median RFU of replicates. A signal, which fluorescence intensity exceeded the background value by a factor of five, was considered as significant. Controls using non-spacered glycans ensured carbohydrate dependence of binding.

## Results and discussion

A wide panel of PSs was used for probing, among them the one from *E. coli* O86 as control (Table 1) and also synthetic histo-blood ABH-epitopes. Illustrating the highly selective recognition by galectins, only few cases of significant reactivity were detected, and the extent of reactivity between the galectins was found to differ markedly (Fig. 2). All three galectins bound to  $\alpha(1-2)$ -rhamnan from *E. coli* with the extent exceeding that obtaining for all ABH glycans.

Despite shared binding properties to the  $\beta$ -galactoside core owing to the homology the galectins can non-uniformly react with glycan epitopes presented in PSs. Also of note, eight PSs present  $\beta$ -galactosides, which would be expected to be galectin binders, but failed to be reactive; particularly, side  $\beta$ -Gal 1-3-connected to core GalNAc in *E. coli* O125,

side  $\beta$ -Gal 1-4-connected to core Glc in *E. coli* O14, inner Gal $\beta$ 1-3(4)Glc(NAc) or Gal $\beta$ 1-3GalNAc in *Proteus mirabilis* O33 and *Proteus mirabilis* OE, in *Proteus penneri* 75, and in *Salmonella enterica* O13,—in all cases Gal moiety has no “forbidden” for galectin binding substituent at O-4 position. Obviously, the spatial presentation and/or structural context can matter, as also valid in the interpretation of cyto- and histochemical results after galectin staining [30, 31].

Equally important, the compilation of the structures of the repeating units of reactive PSs, given in Table 2, disclosed binding properties to non-canonical determinants. As to L-rhamnose, a molecular mimicry with D-galactose has been suggested, rendering a recognition process possible [32]; however, L-Rha monosaccharide in the array (data not shown) was found to be non-binder. Taking into account topological aspects, these studies should not only be performed on free sugars in solution but also on clustered arrangements, which may be required to generate adequate avidity. Methodologically, the array testing has proven to be a convenient way to select candidates for further measuring effects on cell viability when bacteria are exposed to galectins, giving our study model character.

## Conclusions

Our results document the ability of array-presented bacterial PSs to detect galectin reactivity. Binding will not automatically occur if a canonical ligand is part of the PS's repeating unit. Obviously, the mode of presentation plays into this process. Intriguingly, reactivity to PSs without presence of a  $\beta$ -galactoside is detected, stimulating interaction analysis of core-unit sugars due to the potential biomedical relevance of this recognition process, in infection as are effector branch of host defense.

**Acknowledgments** This work was supported by the RAS Presidium Program “Molecular and cell biology” and RFBR grants #1304-00096 and 13-04-00549 as well as EC FP7 funding (GlycoHIT, contract no. 260600; ITN GLYCOPHARM, contract no. 317297). EC FP7 GlycoBioM (no. 259869)

## References

- Gabius, H.-J. (ed.): The Sugar Code. Fundamentals of glycosciences. Wiley-VCH, Weinheim (2009)
- Gabius, H.-J., André, S., Jiménez-Barbero, J., Romero, A., Solís, D.: From lectin structure to functional glycomics: principles of the sugar code. Trends Biochem. Sci. **36**, 298–313 (2011)
- Cambi, A., Koopman, M., Figdor, C.G.: How C-type lectins detect pathogens. Cell. Microbiol. **7**, 481–488 (2005)



4. Vasta, G.R.: Roles of galectins in infection. *Nat. Rev. Microbiol.* **7**, 424–438 (2009)
5. Mey, A., Leffler, H., Hmama, Z., Normier, G., Revillard, J.-P.: The animal lectin galectin-3 interacts with bacterial lipopolysaccharides via two independent sites. *J. Immunol.* **156**, 1572–1577 (1996)
6. Kohatsu, L., Hsu, D.K., Jegalian, A.G., Liu, F.-T., Baum, L.G.: Galectin-3 induces death of *Candida* species expressing specific  $\beta$ 1,2-linked mannans. *J. Immunol.* **177**, 4718–4726 (2006)
7. Cooper, D.N.W.: Galectinomics: finding themes in complexity. *Biochim. Biophys. Acta* **1572**, 209–231 (2002)
8. Kaltner, H., Gabius, H.-J.: A toolbox of lectins for translating the sugar code: the galectin network in phylogenesis and tumors. *Histol. Histopathol.* **27**, 397–416 (2012)
9. Stowell, S.R., Arthur, C.M., Dias-Baruffi, M., Rodrigues, L.C., Gouridine, J.P., Heimburg-Molinaro, J., Ju, T., Molinaro, R.J., Rivera-Marrero, C., Xia, B., Smith, D.F., Cummings, R.D.: Innate immune lectins kill bacteria expressing blood group antigen. *Nat. Med.* **16**, 295–301 (2010)
10. Herget, S., Toukach, P.V., Ranzinger, R., Hull, W.E., Knirel, Y.A., von der Lieth, C.-W.: Statistical analysis of the Bacterial Carbohydrate Structure Data Base (BCSDB): characteristics and diversity of bacterial carbohydrates in comparison with mammalian glycans. *BMC Struct. Biol.* **8**, 35 (2008)
11. Oda, Y., Herrmann, J., Gitt, M.A., Turck, C.W., Burlingame, A.L., Baronides, S.H., Leffler, H.: Soluble lactose-binding lectin from rat intestine with two different carbohydrate-binding domains in the same peptide chain. *J. Biol. Chem.* **268**, 5929–5939 (1993)
12. Hirabayashi, J., Hashidate, T., Arata, Y., Nishi, N., Nakamura, T., Hirashima, M., Urashima, T., Oka, T., Futai, M., Müller, W.E.G., Yagi, F., Kasai, K.-i.: Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. *Biochim. Biophys. Acta* **1572**, 232–254 (2002)
13. Wu, A.M., Wu, J.H., Liu, J.-H., Singh, T., André, S., Kaltner, H., Gabius, H.-J.: Effects of polyvalency of glycotopes and natural modifications of human blood group ABH/Lewis sugars at the Gal $\beta$ 1-terminated core saccharides on the binding of domain-I of recombinant tandem-repeat-type galectin-4 from rat gastrointestinal tract (G4-N). *Biochimie* **86**, 317–326 (2004)
14. Ideo, H., Seko, A., Yamashita, K.: Galectin-4 binds to sulfated glycosphingolipids and carcinoembryonic antigen in patches on the cell surface of human colon adenocarcinoma cells. *J. Biol. Chem.* **280**, 4730–4737 (2005)
15. Stowell, S.R., Arthur, C.M., Slanina, K.A., Horton, J.R., Smith, D.F., Cummings, R.D.: Dimeric Galectin-8 induces phosphatidylserine exposure in leukocytes through poly lactosamine recognition by the C-terminal domain. *J. Biol. Chem.* **283**, 20547–20559 (2008)
16. Rapoport, E.M., André, S., Kurmyshkina, O.V., Pochechueva, T.V., Severov, V.V., Pazynina, G.V., Gabius, H.-J., Bovin, N.V.: Galectin-loaded cells as a platform for the profiling of lectin specificity by fluorescent neoglycoconjugates: a case study on galectins-1 and -3 and the impact of assay setting. *Glycobiology* **18**, 315–324 (2008)
17. Vokhmyanina, O.A., Rapoport, E.M., André, S., Severov, V.V., Ryzhov, I., Pazynina, G.V., Korchagina, E., Gabius, H.-J., Bovin, N.V.: Comparative study of the glycan specificities of cell-bound human tandem-repeat-type galectin-4, -8 and -9. *Glycobiology* **22**, 1207–1217 (2012)
18. Vokhmyanina, O.A., Rapoport, E.M., Ryzhov, I.M., Korchagina, E.Y., Pazynina, G.V., Severov, V.V., Kaltner, H., André, S., Gabius, H.-J., Bovin, N.V.: Carbohydrate specificity of chicken and human tandem-repeat-type galectins-8 in composition of cells. *Biochem. Mosc.* **76**, 1185–1192 (2011)
19. Krzeminski, M., Singh, T., André, S., Lensch, M., Wu, A.M., Bonvin, A.M.J.J., Gabius, H.-J.: Human galectin-3 (Mac-2 antigen): defining molecular switches of affinity to natural glycoproteins, structural and dynamic aspects of glycan binding by flexible ligand docking and putative regulatory sequences in the proximal promoter region. *Biochim. Biophys. Acta* **1810**, 150–161 (2011)
20. Murphy, P.V., André, S., Gabius, H.-J.: The third dimension of reading the sugar code by lectins: design of glycoclusters with cyclic scaffolds as tools with the aim to define correlations between spatial presentation and activity. *Molecules* **18**, 4026–4053 (2013)
21. Huflejt, M.E., Vuskovic, M., Vasiliu, D., Xu, H., Obukhova, P., Shilova, N., Tuzikov, A., Galanina, O., Arun, B., Lu, K., Bovin, N.: Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges. *Mol. Immunol.* **46**, 3037–3049 (2009)
22. Gabius, H.-J.: Influence of type of linkage and spacer on the interaction of  $\beta$ -galactoside-binding proteins with immobilized affinity ligands. *Anal. Biochem.* **189**, 91–94 (1990)
23. Pál, Z., Antal, P., Srivastava, S.K., Hullám, G., Semsei, A.F., Gál, J., Svébis, M., Soós, G., Szalai, C., André, S., Gordeeva, E., Nagy, G., Kaltner, H., Bovin, N.V., Molnár, M.J., Falus, A., Gabius, H.-J., Buzás, E.I.: Non-synonymous single nucleotide polymorphisms in genes for immunoregulatory galectins: association of galectin-8 (F19Y) occurrence with autoimmune diseases in a Caucasian population. *Biochim. Biophys. Acta* **1820**, 1512–1518 (2012)
24. Gabius, H.-J., Wosgien, B., Hendry, M., Bardosi, A.: Lectin localization in human nerve by biochemically defined lectin-binding glycoproteins, neoglycoprotein and lectin-specific antibody. *Histochemistry* **95**, 269–277 (1991)
25. André, S., Jarikote, D.V., Yan, D., Vincenz, L., Wang, G.N., Kaltner, H., Murphy, P.V., Gabius, H.-J.: Synthesis of bivalent lactosides and their activity as sensors for differences between lectins in inter- and intrafamily comparisons. *Bioorg. Med. Chem. Lett.* **22**, 313–318 (2012)
26. Amano, M., Eriksson, H., Manning, J.C., Detjen, K.M., André, S., Nishimura, S.-I., Lehtiö, J., Gabius, H.-J.: Tumour suppressor p16<sup>INK4a</sup>: anoikis-favouring decrease in N/O-glycan/cell surface sialylation by down-regulation of enzymes in sialic acid biosynthesis in tandem in a pancreatic carcinoma model. *FEBS J.* **279**, 4062–4080 (2012)
27. Westphal, O., Jann, K.: Bacterial lipopolysaccharides. Extraction with phenol-water and further applications of the procedure. *Methods Carbohydr. Chem.* **5**, 83–91 (1965)
28. Arbatsky, N.P., Wang, M., Shashkov, A.S., Chizhov, A.O., Feng, L., Knirel, Y.A., Wang, L.: Structure of the O-polysaccharide of *Cronobacter sakazakii* O2 with a randomly O-acetylated L-rhamnose residue. *Carbohydr. Res.* **345**, 2090–2094 (2010)
29. Blixt, O., Head, S., Mondala, T., Scanlan, C., Huflejt, M.E., Alvarez, R., Bryan, M.C., Fazio, F., Calarese, D., Stevens, J., Razi, N., Stevens, D.J., Skehel, J.J., van Die, I., Burton, D.R., Wilson, I.A., Cummings, R., Bovin, N., Wong, C.H., Paulson, J.C.: Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. *Proc. Natl. Acad. Sci. U. S. A.* **101**, 17033–17038 (2004)
30. Habermann, F.A., André, S., Kaltner, H., Kübler, D., Sinowatz, F., Gabius, H.-J.: Galectins as tools for glycan mapping in histology: comparison of their binding profiles to the bovine zona pellucida by confocal laser scanning microscopy. *Histochem. Cell Biol.* **135**, 539–552 (2011)
31. Schlötzer-Schrehardt, U., Andre, S., Janko, C., Kaltner, H., Kopitz, J., Gabius, H.-J., Herrmann, M.: Adhesion/growth-regulatory galectins in the human eye: localization profiles and tissue reactivities as a standard to detect disease-associated alterations. *Graefes Arch. Clin. Exp. Ophthalmol.* **250**, 1169–1180 (2012)
32. Monsigny, M., Kieda, C., Roche, A.-C.: Membrane glycoproteins glycolipids and membrane lectins as recognition signals in normal and malignant cells. *Biol. Cell* **47**, 95–110 (1983)